TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of subjects achieving serum uric acid level ≤ 6 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change from baseline in serum uric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in serum uric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Worst Pain Score of Brief Pain Inventory (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion (%) of the ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of family centered care assessed by parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of family centered care assessed by healthcare staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Up to date for the HPV Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with endoscopic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of steroid diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in H-reflex Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Cutaneous Reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Perception of Cutaneous Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to Move the Limb (Range of Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: levels of serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: levels of prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse events after sequential infusion of CAR-T
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of days of app use
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: percentage of patients who find the Purposeful app to be acceptable
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Medical Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma Lipid Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative change in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Karyotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Accuracy of staining dye selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Signal response using fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antibiotic sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of reported social needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of participants who develop delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Feedback on the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain with inspirometry at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence smoking abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day point prevalence smoking abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delay Discounting Task score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee Subjective Knee Form (IKDC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tegner Lysholm
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Fridericia's Corrected QT Interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in myocardial perfusion and flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in insulin sensitivity in skeletal muscle, liver and adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cardiac uptake and metabolism of hydroxybutyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Headaches Associated With Personal Protective Equipment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of WHO FC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Borg dyspnea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk distances (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Extrapolated to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Percent Recovery of Radioactivity in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Percent Recovery of Radioactivity in Faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NCI-CTCAE toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of wound closure
Endpoint domain: Adverse events/effects
Primary endpoint: ventilator associated events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-17A (IL-17A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-1 beta (IL-1 beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Necrosis Factor (TNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of self-reported symptoms of LTC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: severity (symptoms score) of self-reported symptoms of LTC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of self-donated units of blood obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of safety (laboratory tests, vital signs, and adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year growth rate of subsolid pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of clinically important post-operative atrial fibrillation/atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Atrial Fibrillation Effect on Quality-of-life Questionnaire (AFEQT) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soy-related Gastrointestinal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Soy-related Stool Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Soy-related Stool Consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of treatment-emergent adverse events assessed as drug-related
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of post-operative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in Mini Nutritional Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in value of Body mass Index in kg/(m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nursing student stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress coping style
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Creation of a patent anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neural activity as indexed by BOLD fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Density of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of active cocaine doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GERD-HQRL/RSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pH monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Multiple Sclerosis Functional Composite Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain-derived neurotrophic factor (BDNF) assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: efficacy evaluation indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of acute kidney disease (AKD) leading to chronic kidney disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Efficacy of embolisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of osteoporosis/osteopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone health outcomes
Primary endpoint: Total amount of paracetamol doses (mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in minutes of practice
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in percentage of adherence to practice goal
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of 24-hour Quit Attempts
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Longest Length of Abstinence in Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of Food Security
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: actual weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ideal estimated body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum NT-pro-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Symptoms questionnaire (SANDE) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of fragility fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Chronic breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nutritional ultrasound measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline urinary bisphenol and phthalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of relapse after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all deaths
Endpoint domain: Mortality/survival
Primary endpoint: Oswestery Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nasal Injury Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PAIN score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: FUNCTION
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of HBV HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anxiety levels as measured by SPAS or SCAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in the number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric pH >4 Holding Time Ratio (HTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Gastric pH Over a 24-hour Monitoring Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cigarettes per day from baseline to week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cigarette dependence from baseline to week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette abstinence at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Vertical facial alveolar bone level (VFBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pink esthetic score (PES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with GAD-2 score≥3 and EPDS≥10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic efficiency of antibodies screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of hypercoagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Heartburn-free days/week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Atrial Fibrillation Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life with SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proteomic and metabolomic analysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol use change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol abuse
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol dependence
Endpoint domain: Adverse events/effects
Primary endpoint: Internal cerebral vein velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minimal residual disease negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of clinics enrolled that complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of providers who engage in Practice Facilitation training sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of providers who write a PrEP prescription to women who inject drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of double-stranded DNA damage in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pushing time in the second stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived pushing effort experiences
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Experience levels of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Response speed of the central and peripheral nervous system to a stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preliminary Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Handicap Index-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Postpartum Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline pain outcomes in visual analog scale (VAS) scores at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline functional outcomes in the American Orthopedic Foot and Ankle Score (AOFAS) score at six weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, specificity, and predictive values intraoperatory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity, specificity, and predictive values for postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ASITN cerebral vascular collaterality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area under the curve of plasma apomorphine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal plasma flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete remission of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Real-World Time to Next Treatment (rwTTNT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Melatonin oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in HNC-Specific QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients diagnosed with grade group ≥2 prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cultural Competence and Cultural Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fear Avoidance belief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline ODI score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants who initiate PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in immune response to quadrivalent flu vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rejection Activity Index (RAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of adverse events (AEs)/serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Natural history of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo spells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with conjunctivitis event resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of conjunctivitis event(s) in patients whose conjunctivitis resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who discontinued DUPIXENT® due to conjunctivitis events
Endpoint domain: Adverse events/effects
Primary endpoint: Electronically-measured medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of gastroparesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with locoregional recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Remission state of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythroid precursor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physiological Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological Effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Colorectal Cancer Surveillance Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of RD-index19 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of RD-index19 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes